Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 739,517,120
  • Shares Outstanding, K 949,316
  • Annual Sales, $ 34,124 M
  • Annual Income, $ 5,240 M
  • EBIT $ 13,467 M
  • EBITDA $ 14,994 M
  • 60-Month Beta 0.41
  • Price/Sales 21.95
  • Price/Cash Flow 103.47
  • Price/Book 52.31

Options Overview Details

View History
  • Implied Volatility 36.04% ( +0.39%)
  • Historical Volatility 34.22%
  • IV Percentile 77%
  • IV Rank 41.62%
  • IV High 55.08% on 08/05/24
  • IV Low 22.46% on 06/28/24
  • Put/Call Vol Ratio 0.55
  • Today's Volume 21,310
  • Volume Avg (30-Day) 44,661
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 344,992
  • Open Int (30-Day) 347,424

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 5.49
  • Number of Estimates 8
  • High Estimate 5.58
  • Low Estimate 5.37
  • Prior Year 2.49
  • Growth Rate Est. (year over year) +120.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
711.40 +9.45%
on 11/18/24
846.46 -8.01%
on 12/04/24
+32.42 (+4.34%)
since 11/15/24
3-Month
711.40 +9.45%
on 11/18/24
939.86 -17.16%
on 09/20/24
-127.56 (-14.08%)
since 09/17/24
52-Week
567.02 +37.32%
on 12/21/23
972.53 -19.94%
on 08/22/24
+206.58 (+36.11%)
since 12/15/23

Most Recent Stories

More News
4 Big Drug Stocks That May Continue to Outperform in 2025

The drug and biotech sector saw a strong first half of 2024, driven by an increase in mergers and acquisitions (M&A), robust earnings, and pipeline and regulatory successes. The Zacks Large Cap Pharmaceuticals...

LLY : 778.62 (-0.05%)
VRTX : 469.24 (+0.25%)
GILD : 92.80 (+0.81%)
ABBV : 175.38 (+2.18%)
15 Billion Reasons to Love Eli Lilly Stock Right Now

Lilly just gave investors more reasons to cheer the company on.

LLY : 778.62 (-0.05%)
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?

AbbVie ABBV continued its acquisition spree with the announcement of a definitive agreement to acquire private biotech Nimble Therapeutics, which will add the latter’s lead pipeline candidate, an oral...

NVO : 108.01 (-0.04%)
LLY : 778.62 (-0.05%)
ABBV : 175.38 (+2.18%)
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease

Eli Lilly LLY announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its IL-23p19 antibody Omvoh (mirikizumab) for expanded use in Crohn’s disease...

JNJ : 146.41 (+1.78%)
LLY : 778.62 (-0.05%)
ABBV : 175.38 (+2.18%)
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these companies...

VKTX : 46.70 (-1.12%)
VRTX : 469.24 (+0.25%)
LLY : 778.62 (-0.05%)
PFE : 26.43 (+4.67%)
2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious

As a major pharmaceutical company that is constantly innovating and developing new treatments, Eli Lilly (NYSE: LLY) is always providing investors with additional reasons to consider buying its stock.

LLY : 778.62 (-0.05%)
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs and fought...

NVO : 108.01 (-0.04%)
LLY : 778.62 (-0.05%)
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street

It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. Shares of Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT) more...

VKTX : 46.70 (-1.12%)
WFC : 70.81 (-1.63%)
SMMT : 18.57 (-0.59%)
LLY : 778.62 (-0.05%)
2 Weight Loss Stocks That Are Screaming Buys in December

With drugs like Novo Nordisk 's Wegovy becoming household names over the last couple of years, it's no surprise that there are quite a few opportunities to invest in the burgeoning market for weight-loss...

LLY : 778.62 (-0.05%)
ZLDPF : 114.6000 (+0.12%)
3 Unstoppable Stocks to Buy Right Now

Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals. Three Motley Fool contributors believe they've found stocks in the latter...

AZN : 67.18 (+1.43%)
VRTX : 469.24 (+0.25%)
LLY : 778.62 (-0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 802.51
2nd Resistance Point 795.25
1st Resistance Point 786.94
Last Price 778.62
1st Support Level 771.37
2nd Support Level 764.11
3rd Support Level 755.80

See More

52-Week High 972.53
Fibonacci 61.8% 817.63
Last Price 778.62
Fibonacci 50% 769.78
Fibonacci 38.2% 721.92
52-Week Low 567.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar